Epidermal growth factor
| edit |
Epidermal growth factor or EGF is a growth factor that plays an important role in the regulation of cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds.[1]
History
The discovery of EGF won Dr. Stanley Cohen a Nobel Prize in Physiology and Medicine in 1986[2] and was patented for cosmetic use by Dr. Greg Brown in 1989[3].
Function
EGF results in cellular proliferation, differentiation, and survival. [4]
Mechanism
EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface and stimulating the intrinsic protein-tyrosine kinase activity of the receptor (see the second diagram). The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell - a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR - that ultimately lead to DNA synthesis and cell proliferation.[5]
EGF-family
EGF is the founding member of the EGF-family of proteins. Members of this protein family have highly similar structural and functional characteristics. Besides EGF itself other family members include:[6]
- Heparin-binding EGF-like growth factor (HB-EGF)
- transforming growth factor-α (TGF-α)
- Amphiregulin (AR)
- Epiregulin (EPR)
- Epigen
- Betacellulin (BTC)
- neuregulin-1 (NRG1)
- neuregulin-2 (NRG2)
- neuregulin-3 (NRG3)
- neuregulin-4 (NRG4).
All family members contain one or more repeats of the conserved amino acid sequence:
CX7CX4-5CX10-13CXCX8GXRC
Where X represents any amino acid.[6]
This sequence contains 6 cysteine residues that form three intramolecular disulfide bonds. Disulfide bond formation generates three structural loops that are essential for high-affinity binding between members of the EGF-family and their cell-surface receptors.[7]
EGF therapy
Because of the increased risk of cancer by EGF, inhibiting it decreases cancer risk.[4] Such medications are so far mainly based on inhibiting the EGF receptor. Monoclonal antibodies and small-molecule inhibitors are potential substances for this purpose.
References
- Carpenter G, and Cohen S. (1990). "Epidermal growth factor". J. Biol. Chem. 265 (14): 7709–7712. PMID 2186024.
- The Nobel Prize in Physiology or Medicine 1986 - Presentation Speech
- Method of decreasing cutaneous senescence - Patent 5618544
- a b Herbst RS (2004). "Review of epidermal growth factor receptor biology". Int. J. Radiat. Oncol. Biol. Phys. 59 (2 Suppl): 21–6. doi:. PMID 15142631.
- Fallon JH, Seroogy KB.et al (1984). "Epidermal growth factor immunoreactive material in the central nervous system: location and development". Science 224 (4653): 1107–1109. doi:. PMID 6144184.
- a b Dreux AC, Lamb DJ. et al. (2006). "The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis". Atherosclerosis 186 (1): 38–53. doi:. PMID 16076471.
- Harris RC, Chung E, and Coffey RJ. (2003). "EGF receptor ligands". Exp. Cell. Res. 284 (1): 2–13. doi:. PMID 12648462.
External links
- EGF at the Human Protein Reference Database.
- MeSH Epidermal+growth+factor
Further reading
- Boonstra J, Rijken P, Humbel B, et al. (1995). "The epidermal growth factor". Cell Biol. Int. 19 (5): 413–30. doi:. PMID 7640657.
- Dvorak B (2004). "Epidermal growth factor and necrotizing enterocolitis". Clinics in perinatology 31 (1): 183–92. doi:. PMID 15183666.
- Howell WM (2004). "Epidermal growth factor gene polymorphism and development of cutaneous melanoma". J. Invest. Dermatol. 123 (4): xx-xxi. doi:. PMID 15373802.
|
||||||||||||||||||||||||||
|
|||||
Source: adapted by the editor from Wikipedia, the free encyclopedia; from the article "Epidermal growth factor". Image Credit.